Dong-Mei Feng

Beijing United Family Hospital — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index922citations24works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chemical Synthesis and Analysis(9), Prostate Cancer Treatment and Research(6), Coagulation, Bradykinin, Polyphosphates, and Angioedema(6), Neuropeptides and Animal Physiology(5), Blood Coagulation and Thrombosis Mechanisms(4)

Publications24 total

Association between seasonal influenza vaccination and neonatal outcomes in Shanghai, China
Human Vaccines & Immunotherapeutics·2025Open Access
A new class of bradykinin B1 receptor antagonists with high oral bioavailability and minimal PXR activity
Bioorganic & Medicinal Chemistry Letters·2007· 20 citedOpen Access
Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position
Kluwer Academic Publishers eBooks·2005
2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists
Bioorganic & Medicinal Chemistry Letters·2005· 24 citedOpen Access
2,3-Diaminopyridine Bradykinin B<sub>1</sub> Receptor Antagonists
Journal of Medicinal Chemistry·2004· 42 citedOpen Access
Design and Synthesis of a Pro-Drug of Vinblastine Targeted at Treatment of Prostate Cancer with Enhanced Efficacy and Reduced Systemic Toxicity
Journal of Medicinal Chemistry·2002· 52 cited
A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo.
PubMed·2002· 43 cited
The Synthesis of a Prodrug of Doxorubicin Designed to Provide Reduced Systemic Toxicity and Greater Target Efficacy
Journal of Medicinal Chemistry·2001· 81 cited
PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
PubMed·2001· 52 cited
Design and Synthesis of a Selective PSA Cleavable Peptide-Doxorubicin Prodrug Which Targets PSA Positive Tumor Cells
2001
A peptide–doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo
Nature Medicine·2000· 156 cited
Discovery of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors Incorporating Aminopyridyl Moieties at the P1 Position
Journal of Medicinal Chemistry·1997· 57 citedOpen Access
Development of a Potent Thrombin Receptor Ligand
Journal of Medicinal Chemistry·1995· 60 citedOpen Access
An Antibody Against the Exosite of the Cloned Thrombin Receptor Inhibits Experimental Arterial Thrombosis in the African Green Monkey
Circulation·1995· 94 cited
Design of a potent thrombin receptor radioligand
Peptides·1995
Pharmacological assessment of spantide II analogues
European Journal of Pharmacology·1994· 8 cited
Species Variability in Platelet and other Cellular Responsiveness to Thrombin Receptor-derived Peptides
Thrombosis and Haemostasis·1994· 99 cited
Structure-function relationships in the thrombin receptor agonist peptides
Peptides·1993· 1 cited
Design, Synthesis and Biological Evaluation of Antagonists of LHRH by Criteria of Potency, Safety and Solubility
Zeitschrift für Naturforschung B·1991· 5 citedOpen Access
Position 10 is Critical for Antagonists of the Luteinizing Hormone-Releasing Hormone and for Inhibition of Ovulation in Rats
Zeitschrift für Naturforschung B·1990· 2 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Roger Freidinger(9), Jenny Wai(8), Deborah Defeo-Jones(6), Victor M. Garsky(6), Allen Oliff(6), Karl Folkers(6), Patricia K. Lumma(5), Raymond E. Jones(5), Mark G. Bock(5), Bradley K. Wong(4), Jiunn H. Lin(4), Ruth F. Nutt(4), Anders Ljungqvist(4), Cyril Y. Bowers(4), W. Alexander Van Hook(4), Thomas Connolly(3), Cindra Condra(3), Jules A. Shafer(3), Harri G. Ramjit(3), Daniel F. Veber(3)